As a ligand for the TIM-3 receptor, Gal-9 was shown to promote immunosuppression, e.g., in human cancers, by triggering an exhaustion of CD8+ T cells and impairing the cytotoxicity of NK cells (Kandel et al. 2021; Yang et al. 2021). Here, LGALS9 is linked to cancer.